Brief: Astellas Pharma Inc - Update On Marketing Authorization Application For Avacincaptad Pegol (Acp) In The European Union
27/10/2024 23:06
Oct 28 (Reuters) - Astellas Pharma Inc 4503.T :
* ASTELLAS PHARMA INC - UPDATE ON MARKETING AUTHORIZATION
APPLICATION FOR AVACINCAPTAD PEGOL (ACP) IN THE EUROPEAN UNION
* ASTELLAS PHARMA INC - ANNOUNCED DECISION TO WITHDRAW ITS
MARKETING AUTHORIZATION APPLICATION FROM THE EUROPEAN MEDICINES
AGENCY FOR AVACINCAPTAD PEGOL INTRAVITREAL SOLUTION
Source text: ID:nTSva7ae6d
Further company coverage: 4503.T
(Reporting by Satoshi Sugiyama)
((Satoshi.Sugiyama@thomsonreuters.com;))
Recent news on Astellas Pharma
See all newsBrief: Immuneering To Collaborate With Astellas On Clinical Studies Of Investigational CLDN18.2 Programs In Combination With Atebimetinib For Pancreatic Cancer Patients
Health Rounds: New blood test finds early risk for ovarian cancer
Health Rounds: New blood test finds early risk for ovarian cancer
Refile: Astellas employee imprisoned in China to be released in December, Japanese media report
Table: Astellas Pharma -6-MTH group results (IFRS)